Jean-Pascal Machiels

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Johann S. de Bono, Stéphane Oudard, Mustafa Özgüroğlu et al. · The Lancet · 2010 · 3.3K citations

Medicine, Oncology, Pharmacology +16

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Jean-Pascal Machiels, R. Todd Reilly, Leisha A. Emens et al. · PubMed · 2001 · 459 citations · Full text

Medicine, Immunology, Oncology +15

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

R. Wendel Naumann, Antoine Hollebecque, Tim Meyer et al. · Journal of Clinical Oncology · 2019 · 435 citations

Medicine, Oncology, Pharmacotherapy +17

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers et al. · Investigational New Drugs · 2012 · 399 citations

Medicine, Oncology, Pharmacology +17

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

Jean-Pascal Machiels, Somasundaram Subramanian, Ágnes Ruzsa et al. · The Lancet Oncology · 2011 · 242 citations

Medicine, Oncology, Pharmacotherapy +12